Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction

NCT ID: NCT03904329

Last Updated: 2022-08-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2023-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity paradox In patient with non valvular atrial fibrillation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study role of obesity in outcomes of anticoagulation in patients with non valvular atrial fibrillation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Paradox

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese Patients with non valvular AF

Obese Patients with non valvular AF using oral anti coagulants

Oral Anticoagulant

Intervention Type DRUG

Oral tablets of anti coagulations either warfare or NOACs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Anticoagulant

Oral tablets of anti coagulations either warfare or NOACs

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients presented with non valvular AF
* patients on oral anticoagulant

Exclusion Criteria

* valvular AF
* Mental illness
* History of cerebrovascular stroke
* history of bleeding tendency
* history of Chronic renal failure
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christena amir

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kristen amir

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christen Henan, Ressident

Role: CONTACT

01201558854

Mahmmoed Abd e El saAbour, Assissetant professor

Role: CONTACT

01001202779

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kristen Amir

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Assuit35

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.